Grégory Lazarian

761 total citations
17 papers, 203 citations indexed

About

Grégory Lazarian is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Grégory Lazarian has authored 17 papers receiving a total of 203 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 6 papers in Pathology and Forensic Medicine and 6 papers in Immunology. Recurrent topics in Grégory Lazarian's work include Chronic Lymphocytic Leukemia Research (15 papers), Lymphoma Diagnosis and Treatment (6 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Grégory Lazarian is often cited by papers focused on Chronic Lymphocytic Leukemia Research (15 papers), Lymphoma Diagnosis and Treatment (6 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Grégory Lazarian collaborates with scholars based in France, United States and Sweden. Grégory Lazarian's co-authors include Romain Guièze, Fanny Baran‐Marszak, Catherine J. Wu, Florence Cymbalista, Rémi Letestu, Marie‐Sarah Dilhuydy, Anne Quinquenel, Nadine Varin‐Blank, Loïc Ysebaert and Laura Gardano and has published in prestigious journals such as Journal of Clinical Oncology, Blood and International Journal of Molecular Sciences.

In The Last Decade

Grégory Lazarian

12 papers receiving 200 citations

Peers

Grégory Lazarian

GENET

PFM

IMMUN

ONCOL

HEMAT

Adam Albitar United States

Iryna Kryachok Ukraine

Federico Pozzo Italy

Josie Montegaard United States

Austin I. Kim United States

Maité Cabes United Kingdom

Chiara Lobetti Bodoni Italy

John Hanna United States

Alexander Jethwa Germany

Rose Mantel United States

Adam Albitar United States

Grégory Lazarian

238 ×1.4

GENET

192 ×1.4

PFM

105 ×1.5

IMMUN

40 ×0.7

ONCOL

52 ×1.3

HEMAT

Citations per year, relative to Grégory Lazarian Grégory Lazarian (= 1×) peers Adam Albitar

Countries citing papers authored by Grégory Lazarian

Since Specialization

Citations

This map shows the geographic impact of Grégory Lazarian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Grégory Lazarian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Grégory Lazarian more than expected).

Fields of papers citing papers by Grégory Lazarian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Grégory Lazarian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Grégory Lazarian. The network helps show where Grégory Lazarian may publish in the future.

Co-authorship network of co-authors of Grégory Lazarian

This figure shows the co-authorship network connecting the top 25 collaborators of Grégory Lazarian. A scholar is included among the top collaborators of Grégory Lazarian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Grégory Lazarian. Grégory Lazarian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Hueso, Thomas, Grégory Lazarian, Adrien Chauchet, et al.. (2025). Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real‐World Analysis. eJHaem. 6(2). e70019–e70019.

Lazarian, Grégory, Céline Bourgne, Olivier Tournilhac, et al.. (2025). Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors. Annals of Hematology. 104(5). 2889–2895.

Bisio, Valéria, Karl Balabanian, Nadine Varin‐Blank, et al.. (2024). CLL-235 Metabolic Reprogramming of Bone Marrow Stromal Cells in Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 24. S348–S349.

Rharass, Tareck, Valérie Gratio, Grégory Lazarian, et al.. (2023). Identification of the Axis β-Catenin–BTK in the Dynamic Adhesion of Chronic Lymphocytic Leukemia Cells to Their Microenvironment. International Journal of Molecular Sciences. 24(24). 17623–17623. 4 indexed citations

Lazarian, Grégory, Florence Cymbalista, & Fanny Baran‐Marszak. (2022). Impact of Low-Burden TP53 Mutations in the Management of CLL. Frontiers in Oncology. 12. 841630–841630. 4 indexed citations

Lazarian, Grégory, Ian Morilla, Valéria Bisio, et al.. (2022). Metabolic Reprogramming of Bone Marrow Stromal Cells in Chronic Lymphocytic Leukemia. Blood. 140(Supplement 1). 6996–6997. 1 indexed citations

Éclache, Virginie, Rémi Letestu, Xavier Troussard, et al.. (2021). Characterisation of a New Clinical Presentation of Chronic Lymphocytic Leukemia with Symptomatic Nasopharyngeal Mucosa Involvement. Blood. 138(Supplement 1). 3741–3741. 1 indexed citations

Duchemann, Boris & Grégory Lazarian. (2021). Post–SARS-CoV-2 vaccination acute hemolysis in an older man: don’t forget to look at the blood smear. Blood. 138(21). 2153–2153.

Quinquenel, Anne, Luc‐Matthieu Fornecker, Rémi Letestu, et al.. (2019). Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood. 134(7). 641–644. 88 indexed citations

10.

Lazarian, Grégory, Rémi Letestu, Valérie Vidal, et al.. (2019). A primitive plasma cell leukemia with immunoglobulin (Ig) E. Annales de biologie clinique. 77(5). 557–561. 1 indexed citations

11.

Lazarian, Grégory, Shanye Yin, Elisa ten Hacken, et al.. (2019). B Cell Restricted Expression of Mutated IKZF3 modulates BCR Signaling and Homing Pathways in a Mouse Model of CLL. Blood. 134(Supplement_1). 848–848. 1 indexed citations

12.

Kelaïdi, Charikleia, Thorsten Braun, Alice Marceau‐Renaut, et al.. (2018). Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A. Leukemia Research. 71. 67–74. 3 indexed citations

13.

Lazarian, Grégory, Romain Guièze, & Catherine J. Wu. (2017). Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 35(9). 984–993. 36 indexed citations

14.

Lazarian, Grégory, Eugen Tausch, Virginie Éclache, et al.. (2016). TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes. International Journal of Cancer. 139(8). 1759–1763. 20 indexed citations

15.

Kelaïdi, Charikleia, Thorsten Braun, Grégory Lazarian, et al.. (2014). Long-Term Outcome of Lower-Risk MDS Patients after Immunosuppressive Therapy (IST) with Anti-Thymocyte Globulin (ATG)+/- Cyclosporin A (CsA). Blood. 124(21). 1921–1921.

16.

Bernard, Sophie, Laura Gardano, Christelle Laguillier, et al.. (2014). Inhibitors of BCR signalling interrupt the survival signal mediated by the micro‐environment in mantle cell lymphoma. International Journal of Cancer. 136(12). 2761–2774. 43 indexed citations

17.

Lazarian, Grégory, Rémi Letestu, Fanny Baran‐Marszak, et al.. (2013). Association Of More Than One B Cell Clone Arises In Any Type Of Leukemic Chronic B Cell Disorder. Blood. 122(21). 4161–4161. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact